ONCY
Oncolytics Biotech Inc.
Biotechnology
Market Cap$97M
5Y Perf.-62.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ONCY vs VVOS
Revenue, margins, valuation, and 5-year total return — side by side.
VVOS
Vivos Therapeutics, Inc.
Medical - Devices
Market Cap$5M
5Y Perf.-99.6%
ONCY vs VVOS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ONCY | VVOS |
|---|---|---|
| Industry | Biotechnology | Medical - Devices |
| Market Cap | $97M | $5M |
| Revenue (TTM) | $0.00 | $17M |
| Net Income (TTM) | $-35M | $-17M |
| Gross Margin | — | 55.7% |
| Operating Margin | — | -91.0% |
| Total Debt | $1M | $2M |
| Cash & Equiv. | $16M | $6M |
ONCY vs VVOS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ONCY
VVOS
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Oncolytics Biotech … (ONCY) | 100 | 37.8 | -62.2% |
| Vivos Therapeutics,… (VVOS) | 100 | 0.4 | -99.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ONCY vs VVOS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VVOS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Oncolytics Biotech Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ONCY
Oncolytics Biotech Inc.
The Long-Run Compounder
ONCY is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- -82.5% 10Y total return vs VVOS's -99.7%
- Lower volatility, beta 1.12, Low D/E 17.8%, current ratio 2.82x
- 5.9% margin vs VVOS's -98.8%
Best for: long-term compounding and sleep-well-at-night
VVOS
Vivos Therapeutics, Inc.
The Income Pick
VVOS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.74
- Rev growth 8.9%, EPS growth 80.1%, 3Y rev CAGR -3.8%
- Beta 0.74, current ratio 1.50x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VVOS | 8.9% revenue growth vs ONCY's -38.0% |
| Quality / Margins | ONCY | 5.9% margin vs VVOS's -98.8% |
| Stability / Safety | VVOS | Beta 0.74 vs ONCY's 1.12 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ONCY | +73.7% vs VVOS's -75.7% |
| Efficiency (ROA) | VVOS | -66.7% ROA vs ONCY's -188.3% |
ONCY vs VVOS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
ONCY vs VVOS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLONCYLAGGINGVVOS
VVOSVivos Therapeutics, I…
0leads
ONCYOncolytics Biotech In…
3leads
6 Total Categories
CATEGORYLEADERvs VVOSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ONCY1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ONCY4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ONCY6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ONCY leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
VVOS and ONCY operate at a comparable scale, with $17M and $0 in trailing revenue.
| Metric | ONCYOncolytics Biotec… | VVOSVivos Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $17M |
| EBITDAEarnings before interest/tax | -$35M | -$15M |
| Net IncomeAfter-tax profit | -$35M | -$17M |
| Free Cash FlowCash after capex | -$26M | -$14M |
| Gross MarginGross profit ÷ Revenue | — | +55.7% |
| Operating MarginEBIT ÷ Revenue | — | -91.0% |
| Net MarginNet income ÷ Revenue | — | -98.8% |
| FCF MarginFCF ÷ Revenue | — | -83.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +75.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.7% | -22.5% |
ONCY leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ONCY and VVOS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ONCYOncolytics Biotec… | VVOSVivos Therapeutic… |
|---|---|---|
| Market CapShares × price | $97M | $5M |
| Enterprise ValueMkt cap + debt − cash | $86M | $737,900 |
| Trailing P/EPrice ÷ TTM EPS | -3.00x | -0.30x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.36x |
| Price / BookPrice ÷ Book value/share | 15.70x | 0.42x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ONCY and VVOS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ONCY leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
VVOS delivers a -6.8% return on equity — every $100 of shareholder capital generates $-7 in annual profit, vs $-8 for ONCY. ONCY carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to VVOS's 0.19x. On the Piotroski fundamental quality scale (0–9), VVOS scores 4/9 vs ONCY's 1/9, reflecting mixed financial health.
| Metric | ONCYOncolytics Biotec… | VVOSVivos Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -7.6% | -6.8% |
| ROA (TTM)Return on assets | -188.3% | -66.7% |
| ROICReturn on invested capital | — | -4.2% |
| ROCEReturn on capital employed | -145.5% | -162.5% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.18x | 0.19x |
| Net DebtTotal debt minus cash | -$15M | -$5M |
| Cash & Equiv.Liquid assets | $16M | $6M |
| Total DebtShort + long-term debt | $1M | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ONCY leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ONCY leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ONCY five years ago would be worth $3,147 today (with dividends reinvested), compared to $39 for VVOS. Over the past 12 months, ONCY leads with a +73.7% total return vs VVOS's -75.7%. The 3-year compound annual growth rate (CAGR) favors ONCY at -19.3% vs VVOS's -56.9% — a key indicator of consistent wealth creation.
| Metric | ONCYOncolytics Biotec… | VVOSVivos Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | -8.2% | -73.8% |
| 1-Year ReturnPast 12 months | +73.7% | -75.7% |
| 3-Year ReturnCumulative with dividends | -47.4% | -92.0% |
| 5-Year ReturnCumulative with dividends | -68.5% | -99.6% |
| 10-Year ReturnCumulative with dividends | -82.5% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -19.3% | -56.9% |
ONCY leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ONCY and VVOS each lead in 1 of 2 comparable metrics.
Risk & Volatility
VVOS is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than ONCY's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ONCY currently trades 59.6% from its 52-week high vs VVOS's 8.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ONCYOncolytics Biotec… | VVOSVivos Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 0.74x |
| 52-Week HighHighest price in past year | $1.51 | $7.95 |
| 52-Week LowLowest price in past year | $0.33 | $0.65 |
| % of 52W HighCurrent price vs 52-week peak | +59.6% | +8.3% |
| RSI (14)Momentum oscillator 0–100 | 45.0 | 30.4 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 230K |
Evenly matched — ONCY and VVOS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ONCYOncolytics Biotec… | VVOSVivos Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | 10 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ONCY leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallOncolytics Biotech Inc. (ONCY)Leads 3 of 6 categories
Loading custom metrics...
ONCY vs VVOS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ONCY or VVOS a better buy right now?
Analysts rate Oncolytics Biotech Inc.
(ONCY) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ONCY or VVOS?
Over the past 5 years, Oncolytics Biotech Inc.
(ONCY) delivered a total return of -68. 5%, compared to -99. 6% for Vivos Therapeutics, Inc. (VVOS). Over 10 years, the gap is even starker: ONCY returned -82. 5% versus VVOS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ONCY or VVOS?
By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.
(VVOS) is the lower-risk stock at 0. 74β versus Oncolytics Biotech Inc. 's 1. 12β — meaning ONCY is approximately 53% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Oncolytics Biotech Inc. (ONCY) carries a lower debt/equity ratio of 18% versus 19% for Vivos Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ONCY or VVOS?
On earnings-per-share growth, the picture is similar: Vivos Therapeutics, Inc.
grew EPS 80. 1% year-over-year, compared to 0. 0% for Oncolytics Biotech Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ONCY or VVOS?
Oncolytics Biotech Inc.
(ONCY) is the more profitable company, earning 0. 0% net margin versus -74. 1% for Vivos Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ONCY leads at 0. 0% versus -74. 3% for VVOS. At the gross margin level — before operating expenses — VVOS leads at 60. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ONCY or VVOS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ONCY or VVOS better for a retirement portfolio?
For long-horizon retirement investors, Vivos Therapeutics, Inc.
(VVOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74)). Both have compounded well over 10 years (VVOS: -99. 7%, ONCY: -82. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ONCY and VVOS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.